The development of molecules to delay metastasis in a first-in-line adjuvant setting would require a high safety margin for chronic treatment options. Therefore, testing the anti-metastatic potential of all drugs approved for non-oncology indications is important, as they have a significantly higher safety margin than approved cancer drugs.
Mestastop Solutions has developed a platform called MetGuard®, which tests approved drugs in the METAssay® panel and then takes the lead in the METVivo® panel, conferring in-vitro to in-vivo translational efficacy. This is followed up with retrospective clinical trial studies and employing the METSCAN® platform to understand the relevance of the identified compounds in promoting survival in patients with a five-year follow-up.